Linked Life Data

17284359

Source:http://linkedlifedata.com/resource/pubmed/id/17284359

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2007-3-20
pubmed:abstractText
Therapeutic angiogenesis of coronary and peripheral disease has gone through a period of great hype but has now entered a rational phase. Initial clinical trials with fibroblast growth factor-2 and vascular endothelial growth factor-A have been disappointing, probably owing to suboptimal delivery and incorrect targeting. It is now understood that sustained delivery will be required and that enhancement of collateral formation, rather than angiogenesis, should be targeted. The timing of growth factor therapy might be important as most of these agents protect against ischemic and reperfusion injury, and some may favorably affect post-infarct cardiac remodeling. Preclinical testing of novel delivery strategies, combination therapy as well as novel growth factors and transcription factors pave the way for duly designed and timed clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1471-4892
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
158-63
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Therapeutic angiogenesis in the heart: protect and serve.
pubmed:affiliation
Department of Physiology, CARIM, Maastricht University, Universiteitssingel 50, 6229 ER, Maastricht, The Netherlands.
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't